Search | Clinical Trials Finder

Conditions: Crohn Disease
Interventions: Autologous stem cell transplant, Cyclophosphamide, Thymoglobulin, Methylprednisolone, Vedolizumab; Procedure · Drug
Lead sponsor: Aaron Etra; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease
Interventions: Hematopoietic Stem Cell Transplantation; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Years to 19 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 19
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more

Conditions: Noise-induced Hearing Loss
Interventions: Zonisamide, Methylprednisolone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Graft Versus Host Disease
Interventions: Natalizumab, Methylprednisolone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 7
States / cities: Encinitas, California • West Hills, California • West Hollywood, California + 4 more

Conditions: Multiple Sclerosis (MS)
Interventions: methylprednisolone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Transplant; Failure, Kidney
Interventions: Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids; Drug
Lead sponsor: Gaetano Ciancio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Kidney Transplantation
Interventions: Thymoglobulin, Belatacept, mycophenolate mofetil(MMF), Corticosteroids, Everolimus(EVL), Tacrolimus(TAC); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Knee Osteoarthritis
Interventions: ACP Max™, Depo-Medrol®; Device
Lead sponsor: Arthrex, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Knoxville, Tennessee • Danville, Virginia

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study; Biological · Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
Interventions: Fludarabine, Busulfan, GVHD Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 1 Month to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Cataract Surgery
Interventions: Gatifloxacin, Ketorolac LS, Pred Forte, Moxifloxacin, Nepafenac, EconoPred Plus; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: Not listed
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Corneal Edema, Corneal Defect, Corneal Transplant, Penetrating KeratoPlasty, Anterior Chamber Inflammation, Ocular Pain, Intraocular Pressure
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp; Drug
Lead sponsor: Nicole Fram M.D.; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis, Knee
Interventions: Liposomal bupivacaine, Standard of Care; Drug
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Systemic Lupus Erythematosus
Interventions: Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide; Procedure · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more

Conditions: Osteoarthritis of the Knee
Interventions: Infliximab, Placebo, Standard of Care: Methylprednisolone acetate; Drug
Lead sponsor: Herbert Lindsley, MD; Other
Eligibility: 35 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Myasthenia Gravis
Interventions: Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit), Mesna, Methylprednisolone, G-CSF; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 15 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 1
States / cities: West Columbia, South Carolina

Conditions: Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
Interventions: Dexamethasone, Methylprednisolone, 2% Lidocaine HCl Injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 99 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Migraine Headache
Interventions: bupivicaine, normal saline, methylprednisolone, lidocaine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Lupus Nephritis
Interventions: VIB4920, Placebo for VIB4920; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 13 more

Conditions: Multiple Myeloma
Interventions: Daratumumab 16 mg/kg (Part 1), Daratumumab 8 mg/kg (Part 1), Methylprednisolone, Acetaminophen, Diphenhydramine, Daratumumab (Part 2); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 15
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 12 more

Conditions: Richter's Syndrome, CLL
Interventions: Obinutuzumab, lenalidomide, HDMP; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: ACL Reconstruction
Interventions: Methyl Prednisolone (MP), Standard Post-Operative Pain Control, Surgeon's Standard ACL Postoperative Regimen; Drug · Combination Product
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Autologous Stem Cell Transplant for Crohn's Disease

Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)

Prevention of Noise-induced Hearing Loss

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Alternative Treatment Paradigm for Natalizumab Trial

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

Regimen Optimization Study

ACP Max™ PRP System for Knee Osteoarthritis: A Feasibility Trial

Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Therapeutic Variables in Cataract Surgery

Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery

Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection

Greater Occipital Nerve Block for Migraine Prophylaxis

VIBRANT: VIB4920 for Active Lupus Nephritis

An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction